Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

BACKGROUND: There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. METHODS: We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to September 2017 using the HealthCore Integrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Beachler, Daniel C., de Luise, Cynthia, Jamal-Allial, Aziza, Yin, Ruihua, Taylor, Devon H., Suzuki, Ayako, Lewis, James H., Freston, James W., Lanes, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831235/
https://www.ncbi.nlm.nih.gov/pubmed/33494720
http://dx.doi.org/10.1186/s12885-021-07790-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831235/
https://www.ncbi.nlm.nih.gov/pubmed/33494720
http://dx.doi.org/10.1186/s12885-021-07790-z

Ejemplares similares